Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Up 1,370.0% in June

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 220,500 shares, an increase of 1,370.0% from the June 15th total of 15,000 shares. Based on an average daily volume of 265,400 shares, the days-to-cover ratio is currently 0.8 days. Approximately 43.5% of the company’s shares are sold short.

Bluejay Diagnostics Stock Performance

Shares of Bluejay Diagnostics stock opened at $0.61 on Friday. The stock has a market cap of $205,700.00, a price-to-earnings ratio of -0.01 and a beta of 0.82. The stock has a 50 day moving average price of $3.19 and a 200-day moving average price of $5.61. Bluejay Diagnostics has a one year low of $0.53 and a one year high of $111.84.

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 24,230 shares of the company’s stock, valued at approximately $30,000. Armistice Capital LLC owned about 1.95% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission. 18.47% of the stock is currently owned by institutional investors and hedge funds.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.